Background: Anemia is defined as a decrease in the hemoglobin concentration of blood, which accordingly decreases the oxygen-carrying capacity of red blood cells such that they are unable to meet the body's physiological requirements. Numerous reports have specified that anemia customarily occurs in patients with diabetes with renal insufficiency whereas limited studies have described the occurrence of anemia in people with diabetes prior to indication of renal impairment. Other studies have similarly recognized anemia as a risk factor for the need for renal replacement treatment in diabetes. Understanding the pathogenesis of anemia allied with diabetes can lead to the development of interventions to optimize results in these patients. Purpose: The purpose of this study was consequently to determine the pervasiveness of anemia among patients with type 2 diabetes. Materials and Methods: A total of 50 (25 with type 2 diabetes and 25 controls) participants were enlisted for the current study. Participants' blood samples were analyzed for fasting blood glucose, full blood count and renal function tests among others. The pervasiveness of anemia was then determined statistically. Results: A high incidence of anemia was perceived in the cases. Of the patients with diabetes, 85 % had a hemoglobin concentration that was significantly less (males 10.88±1.78 and females 10.32±1.52) compared to that of controls (males 14.16±1.82 and females 12.49±1.11). A significantly increased fasting blood glucose, urea, sodium, potassium, and calcium ions were observed in the cases (8.02±1.28, 5.21±2.01, 141.08±7.01, 4.84±0.49 and 1.51±0.28 respectively) as compared to the controls (4.57±0.52, 3.61±2.09, 134.86±6.75, 4.38±0.61 and 1.31±0.31 respectively). Finally, a significant association between hemoglobin concentration and fasting blood glucose was also observed in the cases. Conclusions: The findings suggest that a high incidence of anemia is likely to occur in patients with poorly controlled diabetes and in patients with diabetes and renal insufficiency.

No abstract

During the past few decades, extensive researches were conducted to identify serological markers in patients with inflammatory bowel disease (IBD) that can reliably diagnose and monitor disease activity and help in predicting relapses. To date, several serological markers have been identified. This review will address the different serological markers and their clinical significance and applicability in medical practice. Serological markers include antibodies against microbial antigens, peptide antigens, autoantibodies, and basic inflammatory markers. Some serological markers such as anti-Saccharomyces cerevisiae antibodies (ASCA) and antibodies against exocrine pancreas (PAB) help the confirmation of the diagnosis of IBD to differentiate it from other non-IBD. Perinuclear anti-neutrophil cytoplasmic antibodies (pANCA) and ASCA can distinguish Chron’s disease and ulcerative colitis. Certain markers can aid stratification of Chron’s disease including antibodies to Pseudomonas fluorescens associated sequence I2 (Anti-I2), antibodies to bacterial flagellin (Anti-CBir1), ASCA, and antibodies to outer membrane porin C (Anti-OmpC). ASCA and pANCA can predict disease response to therapeutic agents (e.g. Infliximab). ASCA can also unaffected family members at risk of developing Chron’s disease.